Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for treatment of liver cancer
The receptor for advanced glycation-end prod-ucts (RAGE) has been shown to play a central role not only in acute or chronic inflammatory diseases but also in septic shock, late diabetes and cancer. Here we provide a new application of RAGE inhibition in the field of cancer prevention and treatment.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Red light therapy for repairing spinal cord injury passes milestone
Patients with spinal cord injury (SCI) could benefit from a future treatment to repair nerve connections using red and near-infrared light. The method, invented by scientists at the University of…
Insect research is revolutionized by technology
New technologies can revolutionise insect research and environmental monitoring. By using DNA, images, sounds and flight patterns analysed by AI, it’s possible to gain new insights into the world of…
Expanding a lymph node, boosting a vaccine
A biomaterial vaccine enhances and sustains lymph node expansion following vaccination, boosting anti-tumor immunity in an animal model. Each one of us has around 600 lymph nodes (LNs) – small,…
